Antidpressant, Fluvoxamine, Reduces Severe Covid-19 Disease, Study Finds
By Radiant Health EditorsPublished: October 31, 2021
A new study published in Lancet Global Health found that a 10-day course of fluvoxamine (brand name Luvox), a drug commonly prescribed for depression and obsessive-compulsive disorder, significantly reduced the need for hospitalization by 66% and cut deaths by 91% in people at high risk of severe covid-19 disease. A full treatment course with fluvoxamine costs about $10 compared to $700 for a 5-day treatment course with Merck’s antiviral pill, molnupiravir. The expert panel that develops US Covid-19 treatment guidelines has been briefed on the study data and could decide soon about recommending fluvoxamine as an early treatment.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- How To Reduce Screen Time On Phone: 5 Helpful Strategies To Help You Stay Connected With The Real World - October 30, 2024
- 11 Wellness Gift Ideas: Perfect Presents for Her that Nurture Body, Mind, and Soul - October 13, 2024
- 11 Best Indoor Air Purifying Plants: Nature’s Air Filters for Your Home - September 27, 2024
- 11 Best Health and Wellness Books to Read in 2024 - July 4, 2024
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022
- FDA Bans Juul’s E-Cigarettes and Cartridges - June 27, 2022
- Polio Virus Found in London Sewage - June 27, 2022